217 related articles for article (PubMed ID: 31605171)
21. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
[TBL] [Abstract][Full Text] [Related]
23. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
25. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
[TBL] [Abstract][Full Text] [Related]
26. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
[TBL] [Abstract][Full Text] [Related]
27. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
[TBL] [Abstract][Full Text] [Related]
28. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
[TBL] [Abstract][Full Text] [Related]
29. Resection strategies for neuroendocrine pancreatic neoplasms.
Watzka FM; Laumen C; Fottner C; Weber MM; Schad A; Lang H; Musholt TJ
Langenbecks Arch Surg; 2013 Mar; 398(3):431-40. PubMed ID: 23143147
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA
Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
32. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
33. Indications for Surgical Resection in Low-Grade Pancreatic Neuroendocrine Tumors.
Fitzgerald TL; Mosquera C; Vora HS; Vohra NA; Zervos EE
Am Surg; 2016 Aug; 82(8):737-42. PubMed ID: 27657591
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
35. Implementation of Current ENETS Guidelines for Surgery of Small (≤2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry.
Mintziras I; Keck T; Werner J; Fichtner-Feigl S; Wittel U; Senninger N; Vowinkel T; Köninger J; Anthuber M; Geißler B; Bartsch DK;
World J Surg; 2019 Jan; 43(1):175-182. PubMed ID: 30097704
[TBL] [Abstract][Full Text] [Related]
36. Analysis of diagnosis and treatment for pancreatic neuroendocrine neoplasms: results of 47 cases in a single institution.
Lin XS; Zhu CL; Liu CH; Xie F; Zhou HC; Huang Q
Hepatogastroenterology; 2014; 61(136):2383-6. PubMed ID: 25699387
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
[TBL] [Abstract][Full Text] [Related]
38. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
[TBL] [Abstract][Full Text] [Related]
39. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach.
Bertani E; Fazio N; Botteri E; Chiappa A; Falconi M; Grana C; Bodei L; Papis D; Spada F; Bazolli B; Andreoni B
Surgery; 2014 Apr; 155(4):607-14. PubMed ID: 24582492
[TBL] [Abstract][Full Text] [Related]
40. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
Kıvrak Salim D; Bayram S; Gömceli İ; Çekin AH; Karaca M; Koçer M; Yıldız M
Turk J Gastroenterol; 2019 Oct; 30(10):910-916. PubMed ID: 31625933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
